Evaluation of a calculation model to estimate the impact of the COVID-19 pandemic lockdown on visual acuity in neovascular AMD

Martin Stattin\textsuperscript{1,2,3}, Anna-Maria Haas\textsuperscript{1,2}, Daniel Ahmed\textsuperscript{1,2}, Alexandra Graf\textsuperscript{4}, Katharina Krepler\textsuperscript{1,2} and Siamak Ansari-Shahrezaei\textsuperscript{1,2,5,6}

Abstract

\textbf{Purpose:} A model was calculated during the first Austrian coronavirus disease-2019 (COVID-19) pandemic lockdown to estimate the effect of a short-term treatment interruption due to healthcare restrictions on visual acuity (VA) in neovascular age-related macular degeneration (nAMD). The model was compared to the real-life outcomes before treatment restarted.

\textbf{Methods:} Retrospective data-collection of 142 eyes in 142 patients receiving repeated intravitreal injections with anti-VEGF at a retina unit in Vienna in a personalized pro-re-nata regimen prior to the COVID-19 associated lockdown, when treatment was deferred between March 16 and May 4, 2020. During the lockdown, the preliminary data was integrated into pre-existing formulae based on the natural course of the disease in untreated eyes in the long term. Patients were re-scheduled and treated after gradually opening operating rooms. The calculation model was compared to the effective VA change.

\textbf{Results:} The model calculated an overall VA loss of $3.5 \pm 0.8$ letters early treatment diabetes retinopathy study (ETDRS) ($p < 0.001$ [95\% CI:3.3;3.6]) on average compared to $2.5 \pm 6$ letters ETDRS ($p < 0.001$ [95\% CI:1.5;3.5]) as measured with a mean treatment delay of $61 \pm 14$ days after previously scheduled appointments. The total difference between the model exercise and the real-life outcomes accounted for $1 \pm 5.9$ letters ETDRS ($p = 0.051$ [95\% CI: 0.1;1.9]).

\textbf{Conclusion:} The herein presented calculation model might not be suitable to estimate the effective VA loss correctly over time, although untreated eyes and eyes under therapy show similarities after short-term treatment interruption. However, this study demonstrated the potentially negative impact of the COVID-19 pandemic lockdown on patients compromised by nAMD.

\textbf{Keywords}

Anti-vascular endothelial growth factor, calculation model, coronavirus disease 2019, exudative neovascular age-related macular degeneration, intravitreal injection, visual acuity

Date received: 10 November 2020; accepted: 22 September 2021
Introduction

In December 2019, a novel coronavirus (CoV) causing the severe acute respiratory syndrome coronavirus – 2 (SARS-CoV-2) emerged from China.¹ Meanwhile, the global impact of the pandemic named coronavirus disease 2019 (COVID-19) by the World Health Organization in February 2020 has encountered all aspects of daily life.² Restrictions were announced as of March 16, 2020 and maintained until declared otherwise in Austria.³ As one of the first measures, the government gathered health care resources and medical competence. Hospitals were advised to lower all out-patient visits by keeping routine care to a minimum while preparing for worst-case scenarios. Ophthalmologic societies declared recommendations for patient care including the routine administration of intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF).⁴–⁶ The highly frequented Medical Retina Unit of the Department of Ophthalmology at the Rudolf Foundation Hospital, Vienna, Austria was considered a spreading source of the disease in elderly with co-morbidities. COVID-19 has become an emerging situation and required quick adaptation. As an initial consequence and in accordance with the guidelines of the vision academy, patients with only one eye affected by the exudative neovascular type of age-related macular degeneration (nAMD) and scheduled appointments for follow-up and therapy were excluded from ongoing treatment between March 16 and May 4, 2020.⁷ Some patients suspended therapy by choice out of fear of SARS-CoV-2. It was unknown whether eyes would recover once treatment was reinitiated and if their recovery was to the fullest or partially. These regulations implicated a bias on patient selection regarding disease activity and visual acuity (VA). Meanwhile, a calculation model based on the patient’s data was performed to estimate the effect of the treatment deferral raised by the Austrian COVID-19 pandemic lockdown. The calculation originally derived from long-term data of untreated eyes as no comparable model was available at the time.

The purpose of this study was to evaluate the calculation model by quantifying the effective VA change in eyes under therapy after a short-term treatment interruption.

Methods

A retrospective data analysis was performed comparing a calculated predictive model to real-life results. The study protocol adhered to the tenets of the Declaration of Helsinki.

Patients

The data originated from the pool of patients who were originally under investigation for the calculation model and included eyes with previously diagnosed subtypes of macular neovascularization (MNV) secondary to exudative nAMD under current treatment with serial IVI of different anti-VEGF agents (Avastin®, Eylea®) at the tertiary eye care center. In daily routine before the lockdown, patients underwent an ophthalmic examination including best-corrected VA using the Early Treatment Diabetic Retinopathy Study chart at 4 m (ETDRS) - counting every correctly read letter - converted to Snellen, indirect slit-lamp biomicroscopy (Haag-Streit AG, Bern, Switzerland) with dilated pupils using 0.5% tropicamide and spectral domain-optical coherence tomography (SD-OCT; Zeiss Cirrus HD 4000, Carl Zeiss Meditec AG, Jena, Germany) imaging. The decision for ongoing treatment and its respective interval was made after the loading dose of 3 monthly IVI.⁸⁻⁹ Patients continued a pro-re-nata regimen with individual visits and treatment as needed based on the previously elaborated personal interval (supplementary material). Only patients with a VA of 40 letters ETDRS (20/160 Snellen) or better in the affected eye at last follow-up of the pre-lockdown era were enclosed in the study, who had an appointment within the time period of the first COVID-19 associated restrictions and who came back for a follow-up and treatment. Exclusion criteria were eyes of patients with scheduled appointments without treatment over the past 6 months prior to the lockdown or without the necessity of ongoing treatment thereafter. Patients with a sudden onset of VA deterioration in the affected eye and a subsequent urgent intervention (3 patients with subretinal hemorrhage and straight forward surgery) were also excluded from further analysis to minimize the statistical bias in the VA change. For the initial model, 173 eyes in 173 patients were eligible for enrollment. After the last patient was brought in on July 2, 10 patients did not return for the scheduled appointment or ended therapy by choice and 1 patient died. Disease worsening due to a considerable amount of subretinal hemorrhage led to an urgent intervention in 3 patients. In another 14 patients, treatment was not indicated after re-opening. As the data of 3 more patients was missing, the VA of 142 eyes in 142 patients could be further analyzed.

Calculation model

The data of patients were collected via charts, who had a scheduled appointment between March 16 and May 4, 2020. The data were integrated into the equations from Elshout et al.,¹⁰ a modified method originally published by Shah and Del Priore.¹¹ They assumed that VA loss followed a reciprocal course, which fitted the perception in nAMD that VA loss progressed more severely after the beginning of exudation and plateaued to an end-stage VA level over time. Elshout et al. described a double reciprocal general formula based on a literature review with a meta-analysis of published studies including non- or placebo-treated nAMD patients in 2 steps: First, the VA data of all included studies were combined into one plot. The VA data for each lesion type (occult,
minimally and predominantly classic) was separated into three more plots. Second, they automatically translated “months of enrolment” to “months of exudative disease” to extract the correct stage of the disease. In our model, the distribution of VA loss was calculated for the actual treatment delay of 9 weeks although the original model derived from untreated nAMD for up to 80 months. The combined model was applied to the overall patient cohort (n = 142), type 1 MNV (n = 107) was considered as the occult type of nAMD, mixed type MNV (n = 11) as minimally classic and type 2 (n = 8) as predominantly classic nAMD.12

Clinical management

Additional measures were installed to guarantee the best possible safety profile for both, patients and the staff. Eligible patients were contacted by phone and interrogated for respiratory symptoms via questionnaire.13 After consenting, 2 patients at a time were scheduled in 15-min intervals in order to avoid overlaps with a maximum of 40 patients per day starting on May 4 and finishing on July 2. Trained operators with personal protective equipment including filtering face piece 2 or 3 masks conducted SD-OCT B-scans of both eyes.14 Noncontact tonometry and VA testing were performed according to the hygiene standards to avoid a possible spread of the viral load.15 Two medical retina specialists surveyed the images and checked the retina for hemorrhage by slit lamps with handcrafted manufactured 29.7 × 42 cm acrylate safety covers. If eligible, the affected eyes were prepared with 0.5% tropicamide, 2.5% phenylephrine and 5% polyvidone iodine. A resident or fellow together with the nurse staff promptly handled the process of intravitreal anti-VEGF administration. Patients were discharged immediately after the IVI.

Table 1. Demographic data including mean intervals in days for all eyes and separated into MNV subtypes.

|                      | Overall     | Type 1   | Type 2   | Mixed type | Type 3   | Othersa |
|----------------------|-------------|----------|----------|------------|----------|---------|
| n (%)                | 142 (100)   | 107 (75) | 8 (6)    | 11 (8)     | 9 (6)    | 7 (5)   |
| Mean age in years    | 78.1 ± 5.2  | 77.9 ± 7.6| 78.6 ± 9 | 77.6 ± 12  | 84.6 ± 8.4| 71.4 ± 11.7|
| Sex m/f              | 62/80       | 50/57    | 3/5      | 3/8        | 3/6      | 3/4     |
| Laterality r/l       | 78/64       | 56/51    | 5/3      | 47/6       | 8/1      | 5/2     |
| Drug (A/E)           | 85/57       | 65/42    | 5/3      | 7/4        | 6/3      | 2/5     |
| Total interval ± SD  | 1190 ± 1006 | 1164 ± 989| 1313 ± 934| 1452 ± 1231| 590 ± 684| 1802 ± 1106|
| Last interval ± SD   | 57 ± 29     | 56 ± 28  | 68 ± 28  | 58 ± 30    | 63 ± 43  | 43 ± 13 |
| Planned Interval ± SD| 59 ± 28     | 58 ± 27  | 62 ± 26  | 59 ± 41    | 68 ± 33  | 62 ± 29 |
| Actual Interval ± SD | 120 ± 31    | 120 ± 29 | 109 ± 31 | 117 ± 39   | 130 ± 43 | 121 ± 33|
| Delay ± SD           | 61 ± 14     | 62 ± 14  | 48 ± 20  | 57 ± 5     | 63 ± 15  | 60 ± 8  |

MNV = macular neovascularization; *apolypoidal lesion or not classified; m = male; f = female; r = right; l = left; A = Avastin®; E = Eylea®

Table 2. Mean VA development in letters ETDRS (snellen) for all eyes and separated into MNV subtypes.

Before COVID-19 lockdown

|                      | Overall     | Type 1   | Type 2   | Mixed type | Type 3  | Othersa |
|----------------------|-------------|----------|----------|------------|---------|---------|
| Baseline VA          | 70 ± 10.8 (20/40) | 70.2 ± 10.5 (20/40) | 67 ± 8 (20/50 + 2) | 68.7 ± 14 (20/40 - 1) | 68.1 ± 13.3 (20/40 - 2) | 76.4 ± 9.3 (20/32 + 1) |
| Last VA              | 67.8 ± 12.4 (20/40 - 2) | 67.4 ± 13 (20/50 + 2) | 67.1 ± 12.2 (20/50 + 2) | 67.9 ± 10 (20/40 - 2) | 70 ± 9.4 (20/40) | 71.1 ± 10.4 (20/40 + 1) |
| VA change            | -2.3 ± 11.8 (p < 0.001) | -2.8 ± 11.9 (p < 0.001) | 0.1 ± 7.9 (p = 0.246) | -0.8 ± 15.4 (p = 0.008) | 1.9 ± 10.5 (p = 0.621) | -5.3 ± 11 (p = 0.380) |

After COVID-19 lockdown

|                      | Overall     | Type 1   | Type 2   | Mixed type | Type 3  | Othersa |
|----------------------|-------------|----------|----------|------------|---------|---------|
| Effective VA as measured | 65.3 ± 13.5 (20/50) | 65.3 ± 13.8 (20/50) | 62.5 ± 18 (20/50 - 2) | 61.2 ± 11.2 (20/63 + 1) | 69.4 ± 8.8 (20/40 - 1) | 69.9 ± 10.6 (20/40) |
| Effective VA change  | -2.5 ± 6 (p < 0.001) | -2.2 ± 5.6 (p < 0.001) | -4.6 ± 10.3 (p = 0.246) | -6.7 ± 6.8 (p = 0.008) | -0.6 ± 3.2 (p = 0.621) | -1.3 ± 3.6 (p = 0.380) |
| Estimated VA as calculated | 64.3 ± 12.4 (20/50 - 1) | 63.3 ± 13.1 (20/50 - 2) | 51.6 ± 14.2 (20/100 + 2) | 52.2 ± 9.6 (p = 0.001) | -1.3 ± 6 (p < 0.001) | -9.3 ± 6.8 (p < 0.001) |
| Estimated VA change  | -3.5 ± 0.8 (p < 0.001) | -4.1 ± 0.9 (p < 0.001) | -15.5 ± 5.9 (p = 0.001) | -15.7 ± 1 (p < 0.001) | -9.3 ± 6.8 (p < 0.001) | -9.3 ± 6.8 (p < 0.001) |
| Difference effective vs estimated VA change | 1 ± 5.9 (p = 0.051) | 2 ± 5.6 (p = 0.001) | 10.9 ± 9.1 (p = 0.01) | 9 ± 6.8 (p < 0.001) | -9.3 ± 6.8 (p < 0.001) |

VA = visual acuity; ETDRS = early treatment diabetic retinopathy study; MNV = macular neovascularization; COVID-19 = coronavirus disease 2019; *apolypoidal lesion or not classified.
**Statistical analysis**

For the real-life outcomes, first the VA of the last treatment was compared to the VA after the COVID-19 pandemic lockdown using paired t-tests, and mean values with corresponding 95% confidence intervals (95% CI) were calculated. Univariable linear regression models were performed to investigate the following potentially influencing factors on the VA loss since the last treatment: age, sex, drug, total treatment interval, last interval, planned interval, delay, baseline VA and last measured VA. No multivariable regression

![Figure 1.](image)

**Figure 1.** (a) change of visual acuity (VA) in letters early treatment diabetic retinopathy study (ETDRS) before the COVID-19 pandemic lockdown using the penultimate and last VA and development of effective VA as measured in real-life (black line) versus as estimated based on a calculation model (grey line) for the overall cohort and type 1 macular neovascularization (MNV) over time after the lockdown (b) effective letters loss in ETDRS (black line) versus estimated letters loss based on the calculation model (grey line) for the overall cohort and type 1 MNV dependent on the missed interval in months after the lockdown.
model was performed, as only one parameter (subtype) showed a significant result. The allocated interval between the 2 last consultations of each patient resulting in IVI treatment was opposed to the re-scheduled appointment and its delay. Continuous variables were summarized using mean and standard deviation. Categorical variables were summarized using absolute and percent values. Descriptive statistics were used for all eyes as well as separately for the MNV subtypes. The predicted values based on the models were compared to the real-life outcomes using paired t-tests. All analyses were performed using R, release 3.3.3.

Results
For this retrospective data analysis, 142 patients were brought in between May 4 and July 2, 2020. The demographic data was listed in Table 1. In the calculation model, the overall VA loss was estimated as 3.5 ± 0.8 letters ETDRS and hence showed a significant decrease when compared to the last VA before the lockdown (p < 0.001 [95% CI: 3.3;3.6]). The effective VA loss in all eyes accounted for 2.5 ± 0.6 letters ETDRS on average, which also showed a significant decrease in comparison to the last VA (p < 0.001 [95% CI: 1.5;3.5]). The difference between the estimated and the effective VA loss in all eyes was 1 ± 0.5 letters ETDRS (p = 0.51 [95% CI: 0.1;1.9]) on average, which was borderline significant. The effective VA loss in type 1 MNV showed statistical significance (p < 0.001 [95% CI: 1.1;3.2]) as well as the mixed type MNV (p = 0.008 [95% CI: 2.2;11.2]) in contrast to type 2 MNV, type 3 MNV, polypoidal lesions and not classified MNV. Eyes compromised by the mixed type MNV demonstrated a more profound VA loss when compared to type 1 MNV (p = 0.015 [95% CI: 0.9;8.2]). VA development in all eyes and separated into MNV subtypes before and after the lockdown as measured and as calculated including significance levels were presented in Table 2. No significant influence of age (p = 0.701), sex (p = 0.294), drug (p = 0.176), total interval (p = 0.238), missed interval (p = 0.125), last interval (p = 0.627), baseline VA (p = 0.404) or last measured VA (p = 0.650) on the VA loss was observed. The comparison of VA loss in all eyes and type 1 MNV as the most representative subtype were illustrated in Figure 1.

Discussion
In this comparative analysis, the calculation model performed during the Austrian COVID-19 pandemic lockdown showed a borderline significantly higher VA loss than the real-life outcomes. All compared subtypes were investigated independently with a significant decrease in VA, but not all of them were representative owed to their low numbers (Table 2). A tendency towards greater disparity between the estimated and the effective VA loss was likely over time as the data were measured 9 weeks after the previously scheduled appointments. Predictions of a long-term treatment interruption due to the COVID-19 pandemic and its impact on VA behavior in exudative nAMD could not be evaluated. Most investigated eyes and type 1 MNV in particular showed a homogenous VA decline when compared to the estimated VA loss of the model exercise within the time period (Figure 1). This was interesting as the model was originally based on regression formulae for long-term progression of untreated eyes.16–19 It would be conclusive that eyes under previous therapy maintained vision for some time and declined in the latter course of the disease. Our data confirm an effective VA loss of 2.5 letters on average when treatment was withheld for 61 days, considerably similar to untreated eyes. Thus said, this study demonstrated the potentially negative effect of the Austrian COVID-19 pandemic lockdown on care for patients with exudative nAMD and its increasing burden in the near future.20

Data on the natural course of nAMD revealed a progressive VA deterioration in every controlled trial. The era of repeated anti-VEGF therapy led to a stabilization of VA in eyes compromised by this disease as long as the treatment was sustained, independent of the investigated drug.21–24 Real-life data and clinical trials predicted a VA decline once the therapeutic effect of anti-VEGF faded.25,26 Soares et al. recently published data on eyes under anti-VEGF injections that were lost to follow-up for a mean of 12 months and concluded that the recovery would only be partially after re-treatment.27 The herein presented data were different in the way they were acquired. Both, the calculation model as well as the real-life outcomes illustrated the consequences of the COVID-19 pandemic and its associated lockdown on the VA course of eyes which were successfully treated for more than 3 years on average and then had their care suspended for only 9 weeks not self-inflicted by choice but regulated. We were facing a tremendous backlog of patient visits and IVI treatments when we gradually re-opened operating rooms. The forced break of a continuous treatment as shown in this study might not be generalizable. Other countries suggested different regulations on patient care during the COVID-19 pandemic crisis.28–32 Nevertheless, our findings correspond to international outcomes in respect of a VA response to delayed anti-VEGF therapy in nAMD.33–35 The foreseeable future might hold on to reduced schedule volumes compared to pre-COVID-19 levels independent of the underlying coping mechanisms. Better strategies are needed by all involved parties including regulatory authorities, health care providers and medical societies to look ahead and adapt to the era of COVID-19.
the stoppage of care at the Rudolf Foundation Hospital was implemented once and for only 7 weeks, while the re-treatment took not more than 9 weeks. The extrapolation of the model did not involve short-term end points of the natural course of the disease and hence the comparison could be inadequate. Patients affected by the restrictive measures may have missed one treatment on average and could very well recover after ongoing treatment. The study did not pursue VA behavior after treatment was reinitiated. Applied protocols before the lockdown were not based on fixed treatment regimens as executed in pivotal trials but reflected real-life data. Therefore, this study did not differentiate between treatment intervals for the respective drugs.

In conclusion, the herein presented calculation model might not be suitable to estimate the effective VA loss due to a treatment interruption correctly over time. However, visual loss was evident and comparable to untreated eyes after a treatment deferral of 9 weeks. The concept of calculating the damage done by decisions when patients are forced to forego their treatment remains important as it poses questions for future regulations that could be partially answered by this comparative study. Long-term data on real-life outcomes are needed to confirm the herein demonstrated negative effect.

Acknowledgements
The authors wish to thank all patients who participated in this study.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics approval for retrospective studies
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Federal Hospitals Act §15a Abs. 3a states that a vote from the Viennese ethics committee is not obligatory for this study design.

Consent to participate
Informed consent was obtained from all participants.

Consent for publication
The paper has not been published previously and is not under consideration elsewhere. The authors have not published or submitted any related papers from this study. Neither was the paper presented at a meeting. Publication is approved by all authors as well as the responsible authorities. The statistical analysis was carried out by Alexandra Graf, an independent professional without affiliations to our department or the institute.

Availability of data and material
MS and SAS had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The datasets used and/or analyzed to support the findings of this study are available from the corresponding author on reasonable request.

Author contributions
MS is the lead author and guarantor: conceptualization, design, data acquisition, interpretation of data, draft of the article. AMH and DA: data acquisition, analysis and interpretation of data, draft of the article, review and editing. AG: statistical analysis and interpretation of data, draft of the article, review and editing. KK: interpretation of data and thorough revision of the article. SAS: Conception, methodology, supervision, critical revision. All authors read and approved the final version of the manuscript.

ORCID iD
Siamak Ansari-Shahrezaei https://orcid.org/0000-0001-8032-4686

Supplemental material
Supplemental material for this article is available online.

References
1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–1720.
2. Coronavirus, https://www.who.int/health-topics/coronavirus#tab=tab_1 (2021, accessed 16 May 2020).
3. Together against the coronavirus, https://www.oesterreich.gv.at/public.html (2021, accessed 28 April 2020).
4. New recommendations for urgent and nonurgent patient care. American Academy of Ophthalmology, https://www.aao.org/headline/list-of-urgent-emergent-ophthalmic-procedures (2021, accessed 19 April 2020).
5. ESCRS & Eurotimes - COVID 19 Update, http://createsend.com/t/i-C330BB8F528F43D662540EF23F30FEDED (2021, accessed 1 May 2020).
6. Corona & augenärztliche Versorgung – ÖOG, https://www.augen.at/a-bis-z-der-augenmedizin/coronavirus_und_augenarzte.php (2021, accessed 19 April 2020).
7. Korobtechin JF, Loewenstein A, Eldem B, et al. Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol 2020; 258: 1149–1156.
8. Stattin M, Forster J, Graf A, et al. Five-year outcomes of a personalized pro re nata treatment regimen with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Acta Ophthalmol 2019; 97: e131–e133.
9. Statin M, Forster J, Ahmed D, et al. Seven-year visual and anatomical outcomes of intravitreal vascular endothelial growth factor inhibition for neovascular Age-related macular degeneration. J Ophthalmol 2020; 2020: 8345850.
10. Elshout M, Webers CA, van der Reis MI, et al. Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study. BMC Ophthalmol 2017; 17: 20.
11. Shah AR and Del Priore LV. Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots. Am J Ophthalmol 2007; 143: 83–89.
12. Shah AR and Del Priore LV. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration. Ophthalmology 2009; 116: 1901–1907.
13. Borrelli E, Sacconi R, Querques L, et al. Taking the right measures to control COVID-19 in ophthalmology: the experience of a tertiary eye care referral center in Italy. Eye 2020; 34: 1175–1176.
14. Lancet T. COVID-19: protecting health-care workers. Lancet 2020; 395: 22.
15. Seitzman GD and Doan T. No time for tears. Ophthalmology 2020; 127: 980–981. (published online 26 Mar, 2020). Doi: 10.1016/j.ophtha.2020.03.030.
16. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419–1431.
17. Gonzales CR. VEGF Inhibition study in ocular neovascularization (V.I.S.I.O.N.) clinical trial group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005; 25: 815–827.
18. D’Amico DJ, Goldberg MF, Hudson H, et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003; 110: 2372–2383; discussin 2384–2385.
19. Bressler NM. Treatment of Age-related macular degeneration with photodynamic therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001; 119: 198–207.
20. Wong W, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014; 2: e106–e116.
21. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study. Br Med J 2010; 340:c2459.
22. Arevalo JF, Fromow-Guerra J, Sanchez JG, et al. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the pan-American collaborative retina study group at 12 months follow-up. Retina 2008; 28: 1387–1394.
23. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular Age-related macular degeneration. Ophthalmology 2007; 114: 246–252.
24. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432–1444.
25. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010; 94: 2–13.
26. Amoaku W. Ranibizumab: the clinician’s Guide to commencing, continuing, and discontinuing treatment. Eye 2009; 23: 2140–2142.
27. Soares RR, Mellen P, Garrigan H, et al. Outcomes of eyes lost to follow-up with neovascular Age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor. Ophthalmol Retina 2020; 4: 134–140.
28. Corona & augenärztliche Versorgung – OÖG, https://www.augen.at/aktuelles/2020/05/20200529_corona_ordination.php (2021, accessed 19 May 2020).
29. COVID-19: Clinical Eye Care. RANZCO, https://ranzco.edu/home/covid-19-information/clinical-eye-care/ (2020, accessed 19 April 2020).
30. IVT - Epidémie au Covid-19 (2020) SFO-online - Société Française d’Ophthalmologie, https://www.sfo-online.fr/covid-19-infos (updated 21 July, 2020, accessed 7 May 2020).
31. The Royal College of Ophthalmologists. Guidance on restarting medical retina services, https://www.rcophth.ac.uk/wp-content/uploads/2020/07/Guidance-on-restarting-Medical-Retina-Services-1.pdf (2021, accessed 6 March 2021).
32. Canadian Ophthalmological Society. Canadian Retina Society (CRS) position statement on intravitreal injections and the management of retinal diseases during the COVID-19 crisis, https://www.crsrec.ca/files/CRS-Position-Statement-on-Intravitreal-Injection-Treatments-Mar-19-2020.pdf (2021, accessed 6 April 2020).
33. Yang KB, Feng H and Zhang H. Effects of the COVID-19 pandemic on anti-vascular endothelial growth factor factor treatment in China. Front Med (Lausanne) 2020; 7: DOI: 10.3389/fmed.2020.576275. eCollection 2020.
34. Borrelli E, Grosso D, Vella G, et al. Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol 2020; 258(12): 2621–2628. DOI: 10.1007/s00417-020-04955-7.
35. Yeter DY, Dursun D, Bozali E, et al. Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed anti-VEGF treatment. J Fr Ophthalmol 2021; 44(3): 299–306. DOI: 10.1016/j.jfo.2021.02.001.